Integrum AB Class B (DE:6Y1)
FRANKFURT:6Y1
6Y1 Stock Chart & Stats
€0.94
-€0.06(-3.43%)
At close: 4:00 PM EST
€0.94
-€0.06(-3.43%)
Day’s Range― - ―
52-Week Range€0.59 - €3.86
Previous CloseN/A
Volume0.00
Average Volume (3M)8.00
Market Cap
€19.68M
Enterprise Value€151.75M
Total Cash (Recent Filing)€19.06M
Total Debt (Recent Filing)€3.17M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Sep 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding26,027,910
10 Day Avg. Volume6
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)1.07
Price to Sales (P/S)2.01
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)€19.29M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage reduces refinancing and solvency risk, giving management flexibility to fund clinical training, regulatory steps, or selective commercialization spending. That balance-sheet cushion supports multi-month strategic initiatives even during operating cash burn, aiding long-term continuity.
Specialized Business ModelA specialist implant system tied to surgical methods and clinic training creates high switching costs and clinical barriers to entry. Durable demand for replacement components plus training-driven adoption can generate recurring revenue and protect market position versus commoditized prosthetic suppliers.
Prior Revenue TractionSustained revenue growth through 2024 demonstrates prior product-market fit and commercial scalability in target clinics. That historical traction indicates structural demand and a base to rebuild from if execution and margins are corrected, supporting medium-term recovery potential.
Bears Say
Operating Cash BurnPersistent negative operating cash flow signals the core business does not generate sustainable cash, forcing reliance on equity/debt raises or reserves. This constrains strategic choices, risks dilution or covenant pressure, and limits ability to invest in commercialization or clinical scale-up over months.
Margin CollapseA negative gross profit represents a structural pricing, cost, or product-mix problem that erodes unit economics. If unresolved, margins will undermine ability to cover fixed costs, fund R&D or training, and sustain clinic support—threatening long-term viability of the product business model.
Recent Revenue DeteriorationThe shift from prior growth to sharp recent declines suggests demand, reimbursement, or commercial execution issues. Falling top-line, alongside fixed cost commitments, magnifies losses and complicates recovery; sustained declines would impair scale economics and market penetration prospects.
Integrum AB Class B News
6Y1 FAQ
What was Integrum AB Class B’s price range in the past 12 months?
Integrum AB Class B lowest stock price was €0.59 and its highest was €3.86 in the past 12 months.
What is Integrum AB Class B’s market cap?
Integrum AB Class B’s market cap is €19.68M.
When is Integrum AB Class B’s upcoming earnings report date?
Integrum AB Class B’s upcoming earnings report date is Sep 03, 2026 which is in 85 days.
How were Integrum AB Class B’s earnings last quarter?
Integrum AB Class B released its earnings results on Jun 04, 2026. The company reported -€0.06 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.06.
Is Integrum AB Class B overvalued?
According to Wall Street analysts Integrum AB Class B’s price is currently Overvalued.
Does Integrum AB Class B pay dividends?
Integrum AB Class B does not currently pay dividends.
What is Integrum AB Class B’s EPS estimate?
Integrum AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Integrum AB Class B have?
Integrum AB Class B has 26,027,910 shares outstanding.
What happened to Integrum AB Class B’s price movement after its last earnings report?
Integrum AB Class B reported an EPS of -€0.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.083%.
Which hedge fund is a major shareholder of Integrum AB Class B?
Currently, no hedge funds are holding shares in DE:6Y1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Integrum AB Class B
Integrum AB (publ) focuses on the research, development, and global sale of advanced bone-anchored prosthetic solutions. A core offering is the Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant system. This innovative bone-anchored prosthesis integrates directly with the patient's bone through osseointegration, thus circumventing the need for a conventional socket. A significant benefit of the OPRA system is its protective quality, helping to prevent bone fractures from accidental loads. Additionally, Integrum provides Neuromotus, a therapeutic technology designed to mitigate phantom limb pain following an amputation. These sophisticated implant systems are distributed worldwide to hospitals, clinics, and orthopedic professionals. The company was founded in 1962 and is based in Mölndal, Sweden.